Clinical trial
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney…
NCT00004244 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004244 |
|---|---|
| Title | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma |
| Official title | Phase I Trial of rhIL-12 and rHuIFN-a2b in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | The Cleveland Clinic |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | recombinant interferon alfa, recombinant interleukin-12 |
| Enrollment | 30 |
| Start date | Mar 1, 2000 |
| Primary completion | Jul 1, 2005 |
| Completion | Sep 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: